Treatment of Clinically Isolated Syndrome and Relapsing-Remitting Mult
Treatment of Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis with RNS60 Administered Intravenously – a Phase IIa Clinical Trial
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- RNS60
What it measured
Main measures
The change in the mean number of CELs during weeks 8-16 (3 MRIs) compared to the mean total number of CELs during the three baseline MRIs (weeks -8 - 0; 3 MRIs).
Other measures (1)
1) Safety and tolerability measured by the occurrence of adverse events and serious adverse events (see stopping rules).
Safety
Who could take part
Relapsing MS
Show the full criteria
Inclusion criteria
Inclusion: • Clinically isolated Syndrome or Relapsing-remitting MS (45, 46) Exclusion: • Diagnosis of secondary-progressive or primary-progressive MS, as defined by published diagnostic criteria (46).
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To investigate the efficacy of RNS60 administered intravenously on MRI measurements of inflammatory disease activity in CIS and RR-MS patients.
Loading reviews and guidelines…
History
Started
Jun 2014